

ARTICLE

Open Access

SPEN induces miR-4652-3p to target HIPK2 in nasopharyngeal carcinoma

Yang Li¹, Yumin Lv¹, Chao Cheng², Yan Huang³, Liu Yang¹, Jingjing He¹, Xingyu Tao¹, Yingying Hu¹, Yuting Ma¹, Yun Su¹, Liyang Wu¹, Guifang Yu⁴, Qingping Jiang⁵, Shu Liu⁶, Xiong Liu⁷ and Zhen Liu¹

Abstract

SPEN family transcriptional repressor (SPEN), also known as the SMART/HDAC1-associated repressor protein (SHARP), has been reported to modulate the malignant phenotypes of breast cancer, colon cancer, and ovarian cancer.

However, its role and the detail molecular basis in nasopharyngeal carcinoma (NPC) remain elusive. In this study, the SPEN mRNA and protein expression was found to be increased in NPC cells and tissues compared with nonmalignant nasopharyngeal epithelial cells and tissues. Elevated SPEN protein expression was found to promote the pathogenesis of NPC and lead to poor prognosis. Knockdown of SPEN expression resulted in inactivation of PI3K/AKT and c-JUN signaling, thereby suppressing NPC migration and invasion. In addition, miR-4652-3p was found to be a downstream inducer of SPEN by targeting the homeodomain interacting protein kinase 2 (HIPK2) gene, a potential tumor suppressor that reduces the activation of epithelial–mesenchymal transition (EMT) signaling, thereby reducing its expression and leading to increased NPC migration, invasion, and metastasis. In addition, SPEN was found to induce miR-4652-3p expression by activating PI3K/AKT/c-JUN signaling to target HIPK2. Our data provided a new molecular mechanism for SPEN as a metastasis promoter through activation of PI3K/AKT signaling, thereby stimulating the c-JUN/miR-4652-3p axis to target HIPK2 in NPC.

Introduction

Nasopharyngeal carcinoma (NPC) is highly prevalent in Southern China with a much higher incidence than elsewhere¹. It is characterized by high invasion and early metastasis. Patients with NPC are often diagnosed at advanced stage of the disease². Although regional control has been greatly improved by the advances in radiotherapy and chemotherapy, metastasis remains the major

cause of treatment failure³. Accordingly, understanding the molecular mechanisms by of invasion and/or metastasis of NPC is critical for the identification of novel therapeutic targets and formulation of better treatment strategies.

In previous studies, several genes have been reported to be involved in NPC metastasis^{4–6}. SPEN family transcriptional repressor (SPEN), also known as SMART/HDAC1-associated repressor (SHARP), is a large nuclear protein that plays an important role in transcriptional regulation and inactivation of chromosome X⁷. Legare et al. reported that the inactivation of *SPEN* may contribute to breast tumor progression and thus suggested SPEN as a tumor suppressor in ER α -positive breast cancers⁸. In contrast, Feng et al. found that SPEN (SHARP) gene acts as a candidate oncogene, promoting the pathogenesis of human hematopoietic malignancies, breast and colon cancer⁹. Furthermore, Liu et al. demonstrated that SPOCD1(SPEN) may act as a

Correspondence: Xiong Liu (liux1218@126.com) or Zhen Liu (narcissus_jane@163.com)

¹Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 510095 Guangdong, China

²Department of Pediatric Otorhinolaryngology, Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China

Full list of author information is available at the end of the article

These authors contributed equally: Yang Li, Yumin Lv, Chao Cheng, Yan Huang Edited by G. Calin

© The Author(s) 2020



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

carcinogenesis factor by activating the PI3K/AKT pathway to restrained cell apoptosis in Ovarian cancer (OC)¹⁰. These studies suggested that SPEN played a significant and complexed role in tumor pathogenesis. However, the molecular alterations and biological functional involvement of SPEN in the pathogenesis of NPC have not been investigated.

MicroRNAs (miRNAs) are a class of small (17–23 nucleotides) noncoding RNAs that silence mRNA molecules through a degradation or translational inhibition process. They participate in various biological processes, including tumorigenesis and metastasis^{11–13}. Multiple miRNAs have been found to play key roles in regulating the expression of various critical genes during the development of human tumors^{4,14,15}. Several of them were identified as regulators of the progression of NPC, such as miR-374a, miR-184, and miR-3188^{6,16,17}. However, the regulation of miRNAs involving SPEN has not been reported to date.

This study reports a newly discovered miRNA, namely miR-4652-3p, as an oncogenic regulator miRNA, which was found to be upregulated by the potential oncogene

SPEN through the activation of PI3K/AKT/c-JUN signaling. In addition, miR-4652-3p was found to directly target *HIPK2* to participate in the SPEN-mediated promotion of NPC migration, invasion, and metastasis.

Results

SPEN expression and clinicopathological characteristics in NPC

To determine the role of *SPEN* in NPC development, its expression level was analyzed in various NPC cell lines (HONE1, SUNE1, 5-8F, 6-10B, CNE1, and CNE2) and immortalized nasopharyngeal epithelial (NP) cell lines (NP69 and SXSU-1489) by quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The endogenous mRNA level of *SPEN* in all six NPC cell lines was significantly upregulated compared with that in SXSU-1489 nonmalignant immortalized NP cells, although the difference between NPC cells and NP69 nonmalignant NP cells (Fig. 1a) was not significant. As for protein level, a large cohort of 238 NPC tissues and 54 nonmalignant NP tissues were examined by immunohistochemistry (IHC) analysis. *SPEN* expression displayed nuclear and




Table 1 The expression of SPEN in NPC compared with NP tissues.

Group	Cases (n)	SPEN expression		χ^2	P* value
		High expression	Low expression		
NPC	238	141 (59.2%)	97 (40.8%)	29.234	0.000
NP	54	10 (18.5%)	44 (81.5%)		

NPC nasopharyngeal carcinoma, NP nasopharyngeal epithelium.

* χ^2 test was applied to assess the expression of SPEN in NPC and NP

cytoplasmic distribution patterns in both NPC and NP cells with different expression levels (Fig. 1b). Statistical analysis confirmed that among the 238 NPC specimens, 97 (40.8%) had low SPEN expression and 141 (59.2%) had high SPEN expression. Instead, among the 54 NP tissues, low SPEN-expressing tissues accounted for 44 (81.5%), and high SPEN-expressing tissues accounted for 10 (18.5%). In addition, NPC tissues showed higher SPEN expression level than NP tissues ($P < 0.001$, Table 1). In addition, the analysis of the relationship between SPEN expression and the clinicopathological characteristics in patients with NPC revealed no statistically significant association between SPEN expression level and patient age and gender, although SPEN expression was positively correlated with the N (lymph node metastasis) stage ($P < 0.001$; N0–N1 vs. N2–N3), T (tumor size) stage ($P = 0.021$; T1–T2 vs. T3–T4) and clinical stage ($P < 0.001$; I–II vs. III–IV, Table 2). Survival analysis revealed that low-SPEN expressing patients had longer overall survival than high SPEN-expressing patients. ($P = 0.0305$, Fig. 1c).

Knockdown expression of SPEN suppresses cell migration and invasion in vitro and inactivates PI3K/AKT and c-JUN signaling

RNA interference was conducted to knock down SPEN expression in HONE1 and 5–8F cells. SPEN gene expression analysis by qRT-PCR confirmed that, after silencing, its expression was significantly decreased in NPC cells compared with their control cells (Fig. 2a). After SPEN knockdown, the expression of p-PI3K and p-AKT was largely abrogated, as well as the expression of c-JUN (Fig. 2b). In addition, Transwell, Boyden and wound-healing assays to investigate the effect of silencing SPEN on the migration and invasion abilities, NPC cells showed that downregulation of SPEN in HONE1 and 5–8F NPC cells markedly inhibited cell migration and invasion abilities (Fig. 2c, d). Taken together, these findings revealed that inhibition of SPEN decreased NPC cell migration and invasion as well as inactivated PI3K/AKT and c-JUN signaling.

SPEN induces miR-4652-3p expression in NPC cells

To investigate the downstream effector miRNAs regulated by SPEN, an Affymetrix 3.0 miRNA array was used to examine the differential expression of miRNAs between HONE1-siSPEN and HONE1-NC cells (Fig. 3a). Expression analysis by qRT-PCR confirmed that miR-4652-3p expression was downregulated by twofold or more at the mRNA level in SPEN-silenced HONE1 cells compared with HONE1-NC group (Fig. 3b).

MiR-4652-3p promotes NPC cell metastasis in vitro and in vivo

HONE1 and 5–8F cells successfully transfected with miR-4652-3p mimics were used to investigate the effects of miR-4652-3p on migration and invasion alterations in vitro. First, qRT-PCR analysis showed the expression level of miR-4652-3p was higher in HONE1 and 5–8F cells transfected with miR-4652-3p mimics than that in cells transfected with NC (Fig. 3c). In addition, overexpression of miR-4652-3p in HONE1 and 5–8F cells greatly promoted cell migration and invasion abilities (Fig. 3d, e). In addition, we established two NPC cell lines stably overexpressing miR-4652-3p, namely HONE1-LV-miR-4652-3p and 5-8F-LV-miR-4652-3p, by lentivirus-mediated transfection and used them for in vivo studies. Pulmonary metastasis were performed in animal models, developed by injecting NPC cell lines stably overexpressing miR-4652-3p via the tail vein of nude mice. Metastatic nodules in the lung of nude mice were detected under a fluorescence microscope and confirmed by histological analysis. More pulmonary metastases were detected in the miR-4652-3p overexpressing group than in the control (NC) group. No metastases were detected in heart, liver, spleen, kidney, brain, and other organs (Fig. 3f).

Suppression of miR-4652-3p expression inhibits NPC cell migration and invasion

The biological role of miR-4652-3p in NPC pathogenesis was further investigated by introducing miR-4652-3p inhibitors into the HONE1-LV-miR-4652-3p and 5-8F-LV-miR-4652-3p cells stably overexpressing miR-4652-3p. The expression level of miR-4652-3p was found to be elevated in the NPCLV-miR-4652-3p cells compared with LV-NC group, while miR-4652-3p inhibitors significantly reduced the miR-4652-3p expression level (Fig. 4a). Consistent with the role of miR-4652-3p in migration and invasion, inhibition of miR-4652-3p expression by its specific inhibitor suppressed cell migration and invasion in miR-4652-3p-overexpressing HONE1 and 5–8F cells (Fig. 4c, d). The analysis of the mechanism revealed that miR-4652-3p overexpression upregulated the protein expression levels of N-cadherin and vimentin, but downregulated E-cadherin protein level. On the other

Table 2 Correlation between the clinicopathologic characteristics and expression of SPEN in NPC.

Characteristics	Cases (n)	SPEN expression		χ^2	P* value
		High expression	Low expression		
Gender					
Male	181	108 (59.7%)	73 (40.3%)	0.056	0.812
Female	57	33 (57.9%)	24 (42.1%)		
Age (years)					
≤50	153	92 (60.1%)	61 (39.9%)	0.140	0.709
>50	85	49 (57.6%)	36 (42.4%)		
N classification					
N0–N1	122	47 (38.5%)	75 (61.5%)	44.502	0.000
N2–N3	116	94 (81.0%)	22 (19.0%)		
T classification					
T1–T2	110	63 (57.2%)	47 (42.8%)	5.331	0.021
T3–T4	108	78 (72.2%)	30 (27.8%)		
Clinical stage					
I–II	64	25 (39.0%)	39 (61.0%)	14.766	0.000
III–IV	174	116 (66.7%)	58 (33.3%)		

NPC Nasopharyngeal carcinoma, NP normal epithelium.

* χ^2 test was applied to access the associations between SPEN expression and the clinicopathological parameters.

hand, inhibition of miR-4652-3p expression led to opposite effect on the expression levels of these epithelial–mesenchymal transition (EMT) related proteins (Fig. 4b).


MiR-4652-3p directly targets HIPK2

To further explore the mechanisms by which miR-4652-3p promotes NPC cell migration and invasion, various miRNA target prediction software were used to predict miR-4652-3p target genes, including TargetScan, miR-Walk, and mirDIP. A total of 262 potential targets were found in the above-mentioned three databases, which include HIPK2 (Fig. 5a). Western blot analysis confirmed that the HIPK2 protein level was downregulated by miR-4652-3p overexpression, and upregulated by miR-4652-3p inhibitors (Fig. 5b). Simultaneously, co-transfection of miR-4652-3pmimics and *HIPK2* 3' untranslated region (UTR) WT sequence significantly decreased the luciferase reporter activity, whereas the miR-4652-3p inhibitor had the opposite effect. These effects on luciferase activity were abrogated when cells were co-transfected with mutated *HIPK2* 3'UTR (Fig. 5c). Furthermore, depletion of HIPK2 induced the expression of vimentin, but reduced E-cadherin expression, indicating that *HIPK2* silencing restored the EMT signaling suppression caused by inhibition of miR-4652-3p (Fig. 5d). Moreover, HIPK2 expression level was increased after the silencing SPEN in

NPC cells, indicating that HIPK2 is involved in the SPEN/miR-4652-3p-induced NPC cell metastasis (Fig. 5e).

SPEN induces miR-4652-3p expression by modulating PI3K/AKT/c-JUN signaling

To determine the transcriptional regulatory mechanisms of miR-4652-3p expression, the University of California Santa Cruz and Profiler of Multi-Omic data online software were used to analyze a 2-kb upstream region to the transcription start site of miR-4652-3p. A potential c-JUN binding site was predicted at –696 to –708 (Fig. 6a). Accordingly, c-JUN plasmids were introduced into NPC cells, and its effect on miR-4652-3p expression was evaluated by qRT-PCR analysis and Western blot analysis (Fig. 6b, c). The results of the qRT-PCR analysis indicated that miR-4652-3p expression was greatly elevated in HONE1 and 5–8F cells transfected with c-JUN plasmids, suggesting that c-JUN acts as an upstream regulator of miR-4652-3p (Fig. 6d). The binding of c-JUN to the miR-4652-3p promoter region was further confirmed by chromatin immunoprecipitation (ChIP) analysis (Fig. 6e). In a subsequent experiment, LY294002, a specific inhibitor of PI3K, was used to block the PI3K expression in HONE1 and 5–8F cells and its effect on miR-4652-3p function was evaluated. Western blot and qRT-PCR analyses demonstrated that LY294002 decreased the levels of p-PI3K, p-AKT, c-JUN, and miR-4652-3p, but increased HIPK2



expression compared with the control groups (Fig. 6f, g). Our results showed that SPEN induced miR-4652-3p expression by activating PI3K/AKT/c-JUN signaling.

Materials and methods

Cell lines and cell cultures


The six NPC cell lines (5-8F, 6-10B, CNE1, CNE2, HONE1, and SUNE1) and immortalized nonmalignant human nasopharyngeal epithelial NP69 cells used in this study were obtained from the Cancer Research Institute of Southern Medical University (Guangzhou, China). The immortalized nonmalignant human nasopharyngeal epithelial cell line SXSXW-1489 was purchased from SHBIO (SiXin, Shanghai, China). In this study, the NPC and SXSXW-1489 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA). NP69 cells were cultured in a defined keratinocyte serum-free medium supplemented with epidermal growth factor (EGF, Invitrogen, Carlsbad, CA, USA).

RNA isolation and qRT-PCR

Total RNA from each sample was quantified by the NanoDrop2000 and converted to cDNA. cDNA was added to RT 2 Profiler™ PCR Array (TAKARA, JAPAN) and ran in Real-Time PCR instrument (Applied Biosystems, Thermo Fisher Scientific, NY, USA). Primer sequence SPEN (Forward: CGAGCATTTCAAACGATATGGC; Reverse: CCATTTT GTTGACCGAGTTGTG), c-JUN (Forward: GTGCCGAA AAAGGAAGCTGG, Reverse: CTGCGTTAGCATGAGTT GGC), HIPK2 (Forward: CGGACTGGAGAAATACGCA, Reverse: ACAGATGACTGGTGCTGCTTAC), miR-4652-3p (GCGGTTCTGTTAACCCATCCCCCTCA) were synthesized and purchased by Sangon Biotech (Shanghai, China).

Western blot analysis

Whole cell lysates of NPC cells were prepared with a proteinase and phosphatase inhibitor cocktail (Roche, CA, USA). Equal amounts of proteins were resolved to 10% SDS-polyacrylamide gel electrophoresis and transferred to




PVDF membranes (Millipore, Danvers, MA, USA) and blocked with 5% nonfat dry milk in Tris-buffered saline, pH 7.5. Membranes were immuno-blotted overnight at 4 °C. Protein blots were probed with primary antibodies against HIPK2 (Abcam #ab108543), E-cadherin (Cell Signaling Technology #3195), N-cadherin (Cell Signaling Technology #13116), SPEN (Abcam #ab72266), c-JUN (Abcam #ab40766), phosphor-AKT (Cell Signaling Technology #4060), AKT (Cell Signaling Technology #4691), phosphor-PI3K (Cell Signaling Technology #17366), and PI3K (Cell Signaling Technology #4292). Goat anti-rabbit IgG HRP-linked antibody (1:10,000) and goat anti-mouse IgG HRP-linked antibody (1:10,000) were from Proteintech (Rosemont, IL, USA). Signals were

visualized by chemiluminescence (Bio-rad, Hercules, California) and quantitated using a Quantity One system (Bio-Rad, Hercules, CA, USA).

Immunohistochemical staining


Two hundred and thirty-eight (238) paraffin-embedded NPC specimens and fifty-four (54) cases of nonneoplastic nasopharyngeal mucosal tissue were collected from Nanfang Hospital of Southern Medical University without any therapy before sampling. Among 238 NPC cases, 181 cases are male and 57 are female, ranged from 20 to 84 years old of age (median 58.9 years old). The clinical process was approved by the Ethics Committees of Nanfang Hospital of Southern Medical University and the



informed consent were obtained from patients. Two independent pathologists (Dr. Zhen Liu and Qingping Jiang) performed the blinded scoring. IHC staining scores were judged by the following criteria: A staining index (ranging from 0 to 12) was determined by the intensity of SPEN staining (0 = negative, 1 = weakly positive, 2 = moderate positive, 3 = strongly positive), multiplied by the proportion score of immunopositive tumor cells (0% = 0, <10% = 1, 10% to <50% = 2, 50% to <75% = 3, \geq 75% = 4). A minimum of 300 epithelial cells were counted for each sample and 3 or higher scores were classified as high SPEN expression.

RNA interference

The siRNAs specifically against SPEN and HIPK2 gene and their corresponding scrambled siRNAs were transfected into NPC cells in six-well plates using Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer's instructions. The scramble small-interfering RNA (NC) and the siRNAs targeting SPEN (#2, 5'-CCAAGATCGTACATATTAT-3'; #3, 5'-GGA TCATGGTGCATCCACA-3'), and HIPK2 (#1, 5'-GC UCACGGAAGCCAUUAUATT-3', #2, 5'-GCGGACC ACACAACCUAUUTT-3') were synthesized and purchased from Ribobio (Guangzhou, China).



In vitro cell migration, invasion and wound-healing assays

For migration assay, 1×10^4 cells in serum-free culture medium were added to the upper chamber, and the lower chamber was filled with 10% FBS culture media. Micro pore size of transwell membrane is 8 μm. After incubation, the filter was fixed with methanol, stained with crystal violet solution, and counted under a microscope in three random fields (×200).


For invasion assay, transwell membranes were pre-coated with 35 μl diluted matrix matrigel (BD Biosciences, USA) for 30 min. 1×10^5 Cells adhering to the lower surface were counted the same way with the cell migration assay. Cells that migrated and invaded were quantified by counting cells in three random fields per filter.

For wound-healing assay, 4×10^6 cells were seed to confluence in a six-well plate, then cultured with serum-free medium. Artificial wound tracks were created by straight scraping confluent cell with a pipette tip. The ability of the cells to migrate into the wound area was

assessed at 0 and 24 h after scratching. *miRNA array following* siSPEN Interference of SPEN in HONE1 cells was sent to Shanghai OE Biotech. Co., Ltd. (Shanghai, China) for miRNA biochip correlation analysis. The biochip used in this study was the SurePrint Agilent Human miRNA Microarrays (Release 21.0, ID:070156) obtained from (Agilent Technologies, Santa Clara, CA, USA).

Establishment of NPC cell lines stably overexpressing miR-4652-3p

HONE1 and 5-8F cells were infected with a lentiviral expression vector carrying miR-4652-3p, which was constructed by GeneChem Co., Ltd. (Shanghai, China). MiR-4652-3p overexpressing cells with green fluorescent protein signals were selected for further experiments by screening with puromycin. Total RNA was extracted from these cells and reverse transcribed into cDNA to measure the infection efficiency by qRT-PCR analysis.



In vivo metastasis assay in nude mice

Five female BALB/c nude mice (4-week old) were randomly divided into four groups and injected with HONE1/5-8F-miR-4652-3P or HONE1/5-8F-miR-control cells. Briefly, 1×10^6 cells were injected intravenously through the tail vein

of each nude mouse in a laminar flow cabinet. Four weeks after injection, the mice were sacrificed and examined for routine tissue processing. Lung tissues were then fluorescently imaged using the LT-9MACIMSYPLUS whole-body imaging system (Light Tools Research, Encinitas, CA, USA).

Subsequently, the Image J software (NIH, Bethesda, MD, USA) was used to quantify the fluorescence signal intensity emitted from lung tissues. All animal experiments were conducted according to the standard institutional guidelines of Guangzhou Medical University. All animal experimental procedures were performed according to the Guidelines for the Care and Use of Laboratory Animals (NIH publications Nos. 80–23, revised 1996).

Dual luciferase reporter assay

The prediction software used predicted that *HIPK2* is probably a direct target of miR-4652-3p. The 3'UTR fragment of *HIPK2* was amplified using PCR primers and cloned into the psiCHECK-2 vector. Site-directed mutagenesis of the miR-4652-3p binding site at the *HIPK2* 3' UTR was performed using the GeneTailor system (Invitrogen). The wild (wt) or mutant (mt) type of the *HIPK2* 3'UTR vector, psiCHECK-2 were co-transfected into the cells with miR-4652-3p mimics or inhibitors. The tests were independently performed in triplicate using a dual luciferase assay kit (Promega Corp., Madison, WI, USA) according to the manufacturer's instructions.

Chromatin immunoprecipitation (ChIP) assay

ChIP analysis was performed using a ChIP assay kit (catalog: 17-371; Millipore, Billerica, MA, USA) according to the manufacturer's instructions to determine whether c-JUN binds to the promoter of miR-4652-3p. First, cells were transfected with a c-JUN plasmid and fixed with 1% formaldehyde. The cross-linked DNA is sonicated, cut to a length of 200–1000 base pairs, and then subjected to an immunoselection process, which requires the use of an anti-c-JUN antibody (1:50; Cell Signaling Technology (CST), Inc., Danvers, MA, USA). Ultimately, the agarose gel electrophoresis results reveal whether the DNA fragment of the putative c-JUN binding site was present in the miR-4652-3p promoter.

Statistical analysis

Statistical analyses were performed using the SPSS 16.0 software (IBM Corp., Armonk, NY, USA) and GraphPad Prism v5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Data are presented as the mean \pm SEM. For migration and invasion assays, statistical significance was determined using the Student's two-tailed *t* test for two groups and one-way analysis of variance (ANOVA) for multiple groups. Immunohistochemistry analysis results were analyzed by the chi-square (χ^2) test. Survival analysis was performed using the Kaplan–Meier method. A *P* value of < 0.05 was considered as statistically significant. **P* < 0.05 , ***P* < 0.01 , and ****P* < 0.001 .

Discussion

SPEN has been reported to play a dual role in tumor development^{8–10}. However, its biological function and

molecular mechanism in NPC have not been elucidated. In this study, we first observed the upregulated mRNA expression of SPEN in NPC cells compared with immortalized nasopharyngeal epithelial (NP) cell lines (NP69 and SXS-1489). In addition, IHC analysis revealed elevated SPEN protein expression level in NPC tissues compared with NP tissues. High expression of SPEN was identified as an independent predictor and cause of the poor outcome of NPC patients. Further, knocking down SPEN suppressed the migration and invasion of NPC cells. These findings were similar to Légaré and Liu et al.'s reports in breast cancer and ovarian cancer^{9,10}, which demonstrated that dysregulation of SPEN was significantly involved in the development of NPC, suggesting that it plays a potential tumor metastasis promoter in NPC.

Molecular mechanisms underlying the migration and invasion of tumor cells have been intensively studied^{17,18}. PI3K/AKT is a key oncogenic signal that had been widely documented to activate EMT pathway and thus promote tumor migration, invasion, and metastasis^{19,20}. In previous investigation, we also observed that dysregulated PI3K/AKT and its downstream EMT participated in some tumor-related gene-mediated NPC migration, invasion, and metastasis^{6,12}. In this study, analog to Liu et al.'s data¹⁰, we found that suppressing SPEN reduced PI3K/AKT and its downstream EMT signal. Furthermore, c-Jun, an oncogenic transcription factor was also decreased in SPEN-suppressed NPC cells. These data further supported SPEN as a tumor metastasis promoter in NPC.

MiRNAs as intermediate regulators have been widely shown to participate in tumor-related gene-mediated signal network^{21–23}. In previous studies, we also observed that miR-133a-3p, miR-5188, miR-3188, miR-374a, and miR-296-3p, respectively were modulated by VPS33B, HBx, FOXO1, PDCD4, and HDGF involving in the tumor pathogenesis induced by these genes^{5,6,12,13,20,24,25}. In order to further explore the molecular mechanism of metastasis induced by SPEN in NPC, Affymetrix miRNA array and qRT-PCR were used to identify the differential miRNAs in SPEN-knocking down cells. The data revealed that miR-4652-3p was a significantly positive-regulator of SPEN and might function as a tumor-promoted role in NPC cells. Consistent with our speculation, miR-4652-3p was found as a tumor metastasis promoter accelerating the metastasis of NPC. However, this data were not consistent with Li's report for miR-4652-3p in malignant meningioma²⁶, which suggests the complexity of miR-4652-3p in tumors.

In order to explore the mechanisms by which miR-4652-3p enhanced NPC cell migration, invasion and metastasis, bioinformatics were used to predict target genes through Targetscan, miRWalk, and mirDIP. Two hundred and sixty-two potential targets were found in all the above three databases, including *HIPK2*. The serine/threonine kinase *HIPK2*, which was identified as a

potential tumor suppressor in human neoplasms, is involved in transcriptional regulation and apoptosis^{27–32}. Furthermore, HIPK2 inhibition was reported to promote EMT and subsequent cell invasion in bladder cancer²⁷. In this study, we found that miR-4652-3p directly targeted HIPK2 and HIPK2 silencing abrogated the EMT signaling alteration caused by miR-4652-3p interference. These data demonstrated that miR-4652-3p targets HIPK2 to activate EMT signal and function as a promoter of tumor metastasis.

In prior study, we have shown that SPEN induces mir-465-3p expression, However, the mechanism by which SPEN regulates miR-4652-3p expression has not been elucidated. It is well known that transcript factor-mediated miRNA transcription expression has been widely documented in tumors^{11,20,25}. In this study, we first predicted the possible transcription factors binding to the miR-4652-3p promoter. Notably, among them, c-JUN was predicted as a potential transcription factor of miR-4652-3p. Overexpressed c-JUN markedly increased the expression of miR-4652-3p. In addition, the ChIP analysis indicated that c-JUN binds to the miR-4652-3p promoter.

C-JUN is an oncogenic transcription factor known as a key regulator of major biological processes³³ and recognized as a downstream positive regulator of PI3K/AKT signaling^{15,34–36}. In previous studies, we also observed that c-JUN was induced by PI3K/AKT signal to modulate the expression of miRNAs expression in tumors including NPC^{14,24,37}. Interestingly, we had observed that SPEN positively regulated the expression of PI3K/AKT/c-JUN and thus speculated that SPEN modulates the miR-4652-3p/HIPK2-mediated EMT signaling through the PI3K/AKT/c-JUN pathway. In line with this notion, suppressing p-PI3K with its specific inhibitor LY294002 reduced the activation of p-AKT/c-JUN, which further downregulated miR-4652-3p expression, thereby increasing the HIPK2-induced inhibition of EMT signaling. Finally, we confirmed that SPEN was negatively correlated with HIPK2 protein expression in NPC cells and immortalized nasopharyngeal NP69 cells.

Overall, our study demonstrated for the first time that elevated SPEN might be used as a useful prognostic biomarker in NPC. Specifically, it activates PI3K/AKT/c-JUN to modulate miR-4652-3p/HIPK2 axis, which in turn activates EMT signaling and promotes NPC metastasis. Our findings reveal a novel pathway involved in NPC pathogenesis and broaden our understanding of NPC metastasis, which offer treatment options for improving the survival of patients with NPC.

Acknowledgements

This study was funded by the Natural Science Foundation of China (No. 81872198), Supporting Plan for Special Talents in Guangdong Province (No. 2016TQ03R466), Nature Science Fund of Guangdong Province (Nos. 2019A1515012194, 2017A030313702, 2017A030313701), Guangzhou Science

and Technology Funding Projects (Nos. 201804010023, 201707010425), and the National Funds of Developing Local Colleges and Universities (No. B16056001), Shenzhen Key Laboratory of Viral Oncology (ZDSYS201707311140430), Seedling Program of Shenzhen Hospital of Southern Medical University (2017MM03).

Author details

¹Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, State Key Laboratory of Respiratory Disease, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou 510095 Guangdong, China. ²Department of Pediatric Otorhinolaryngology, Shenzhen Key Laboratory of Viral Oncology, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China. ³Department of Pathology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. ⁴Department of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. ⁵Department of Pathology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. ⁶Department of Breast Surgery, Guiyang Maternal and Child Healthcare Hospital, Guiyang 550003 Guizhou, China. ⁷E.N.T. Department of Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Author contributions

Zhen Liu, Chao Cheng and Xiong Liu designed the study. Yumin Lv, Liu Yang, Jingjing He, Xingyu Tao, Yingying Hu, Yuting Ma, Yun Su, Liyang Wu and Yang Li conducted the experiments. Zhen Liu and Yang Li wrote the manuscript. Guifang Yu, Yan Huang, Shu Liu and Qingping Jiang formed the data analysis and helped to draft the manuscript. All authors read and approved the final manuscript.

Data availability

The data generated, used, and analyzed in the current study are available from the corresponding author in response to reasonable request.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 12 December 2019 Revised: 10 June 2020 Accepted: 15 June 2020

Published online: 02 July 2020

References

- Wei, K. R. et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013. *Chin. J. Cancer* **36**, 90 (2017).
- Tang, L. L. et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. *Cancer Lett.* **374**, 22–30 (2016).
- Lee, A. W. et al. The battle against nasopharyngeal cancer. *Radiother. Oncol.* **104**, 272–278 (2012).
- Cai, L. M. et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. *Oncogene* **34**, 2156–2166 (2015).
- Deng, X. et al. miR-296-3p negatively regulated by nicotine stimulates cytoplasmic translocation of c-Myc via MK2 to suppress chemotherapy resistance. *Mol. Ther.: J. Am. Soc. Gene Ther.* **26**, 1066–1081 (2018).
- Zhen, Y. et al. miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCC4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin. *Oncogene* **36**, 275–285 (2017).
- Sanchez-Pulido, L. et al. SPOC: a widely distributed domain associated with cancer, apoptosis and transcription. *BMC Bioinform.* **5**, 91 (2004).
- Legare, S., Chabot, C. & Basik, M. S.P.E.N. a new player in primary cilia formation and cell migration in breast cancer. *Breast Cancer Res.* **19**, 104 (2017).

9. Feng, Y. et al. Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation. *Cancer Res.* **67**, 482–491 (2007).
10. Liu, D., Yang, Y., Yan, A. & Yang, Y. SPOCD1 accelerates ovarian cancer progression and inhibits cell apoptosis via the PI3K/AKT pathway. *OncoTargets Ther.* **13**, 351–359 (2020).
11. Li, Y. et al. Chemical compound cinobufotalin potently induces FOXO1-stimulated cisplatin sensitivity by antagonizing its binding partner MYH9. *Signal Transduct. Target. Ther.* **4**, 48 (2019).
12. Liang, Z. et al. VPS33B interacts with NESG1 to modulate EGFR/PI3K/AKT/c-Myc/P53/miR-133a-3p signaling and induce 5-fluorouracil sensitivity in nasopharyngeal carcinoma. *Cell Death Dis.* **10**, 305 (2019).
13. Zhao, M. et al. Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/beta-catenin signaling in non-small-cell lung cancer. *Cell Death Dis.* **9**, 78 (2018).
14. Lin, X. et al. RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells. *Signal Transduct. Target. Ther.* **3**, 23 (2018).
15. Ye, Y. et al. EBV-miR-BART1 is involved in regulating metabolism-associated genes in nasopharyngeal carcinoma. *Biochem. Biophys. Res. Commun.* **436**, 19–24 (2013).
16. Chen, X. et al. SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. *Cell Death Dis.* **9**, 982 (2018).
17. Cheng, W. C. et al. RAB27B-activated secretion of stem-like tumor exosomes delivers the biomarker microRNA-146a-5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer. *Int. J. Cancer* **145**, 2209–2224 (2019).
18. Ge, Q. et al. miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer. *Int. J. Cancer* **144**, 3043–3055 (2019).
19. Manoel-Caetano, F. S. et al. Upregulation of the APE1 and H2AX genes and miRNAs involved in DNA damage response and repair in gastric cancer. *Genes Dis.* **6**, 176–184 (2019).
20. Lin, X. et al. HBX-induced miR-5188 impairs FOXO1 to stimulate beta-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma. *Theranostics* **9**, 7583–7598 (2019).
21. Qiu, Y. Y. et al. lncRNA-MEG3 functions as a competing endogenous RNA to regulate Treg/Th17 balance in patients with asthma by targeting microRNA-17/ RORgammat. *Biomed. Pharmacother.* **111**, 386–394 (2019).
22. Zhang, H. et al. Exosomal circRNA derived from gastric tumor promotes white adipose browning by targeting the miR-133/PRDM16 pathway. *Int. J. Cancer* **144**, 2501–2515 (2019).
23. Thakur, C. et al. Loss of mdig expression enhances DNA and histone methylation and metastasis of aggressive breast cancer. *Signal Transduct. Target. Ther.* **3**, 25 (2018).
24. Zhao, M. et al. miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. *Nat. Commun.* **7**, 11309 (2016).
25. Fu, Q. et al. miRomics and proteomics reveal a miR-296-3p/PRKCA/FAK/Ras/c-Myc feedback loop modulated by HDGF/DDX5/beta-catenin complex in lung adenocarcinoma. *Clin. Cancer Res.* **23**, 6336–6350 (2017).
26. Li, T. et al. LINC00702/miR-4652-3p/ZEB1 axis promotes the progression of malignant meningioma through activating Wnt/beta-catenin pathway. *Biomed. Pharmacother.* **113**, 108718 (2019).
27. Tan, M. et al. Downregulation of homeodomain-interacting protein kinase-2 contributes to bladder cancer metastasis by regulating Wnt signaling. *J. Cell. Biochem.* **115**, 1762–1767 (2014).
28. Hofmann, T. G., Glas, C. & Bitomsky, N. HIPK2: a tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. *BioEssays: N. Rev. Mol. Cell. Dev. Biol.* **35**, 55–64 (2013).
29. D’Orazi, G. et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. *Nat. Cell Biol.* **4**, 11–19 (2002).
30. Kim, E. A. et al. Homeodomain-interacting protein kinase 2 (HIPK2) targets beta-catenin for phosphorylation and proteasomal degradation. *Biochem. Biophys. Res. Commun.* **394**, 966–971 (2010).
31. Pierantoni, G. M. et al. The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissues. *Biochem. Biophys. Res. Commun.* **290**, 942–947 (2002).
32. Nardinocchi, L. et al. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. *Biochim. Biophys. Acta* **1793**, 368–377 (2009).
33. Lin, X. et al. Silencing MYH9 blocks HBx-induced GSK3beta ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. *Signal Transduct. Target. Ther.* **5**, 13 (2020).
34. Zeng, Q. et al. Inhibition of ZIP4 reverses epithelial-to-mesenchymal transition and enhances the radiosensitivity in human nasopharyngeal carcinoma cells. *Cell Death Dis.* **10**, 588 (2019).
35. Liu, W. et al. DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-kappaB pathway in colorectal cancer. *Int. J. Cancer* **142**, 2068–2079 (2018).
36. Nepstad, I. et al. Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. *Signal Transduct. Target. Ther.* **4**, 20 (2019).
37. Yu, X. et al. Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. *Cell Death Dis.* **4**, e634 (2013).